Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoTriColor: LY3200882 and Capecitabine in Advanced CRC
NCT04031872Phase 2Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2020
- Primary completion
- Jan 2020
01
Overview
A Phase 2 trial of ly3200882 in colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Planned start Jan 2020; status: withdrawn.
02
Drugs
ly3200882
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04031872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04031872.